Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or
ischemic events in patients with coronary artery disease treated with percutaneous coronary …

Aim To assess the effects of 1-or≥ 3-month dual antiplatelet therapy (DAPT) in high
bleeding risk (HBR) patients who received biodegradable-polymer sirolimus-eluting stents …

Background It remains unclear whether P2Y12 inhibitor monotherapy preserves ischemic
protection while limiting bleeding risk compared with dual antiplatelet therapy (DAPT) after …

Coronary stents have revolutionized the treatment of coronary artery disease. Compared
with balloon angioplasty, bare-metal stents (BMSs) effectively prevented abrupt vessel …